Thursday 16 October, 2025
Objectives: AZD002 is being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). In healthy volunteers it has been shown…
Read morePoster: Other drugs and diseases
Population Pharmacokinetics of Mefloquine and its Major Metabolite in Healthy Volunteers.
Thursday 16 October, 2025
Objectives: Mefloquine has a pivotal position as an important first-line anti-malarial drug and needs to be used to prevent resistance….
Read moreComparative pharmacokinetics of dimethoate poisoning in the minipig and human
Thursday 16 October, 2025
Objectives: Organophosphorus pesticide (OP) poisoning is a major clinical problem in rural Asia. In contrast to other class II OPs,…
Read moreModelling red blood cell survival data
Thursday 16 October, 2025
Objectives: The survival time of red blood cells (RBCs) is commonly determined based on labelling experiments and an estimate of…
Read morePopulation pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients on a calcineurin inhibitor free regimen
Thursday 16 October, 2025
Objectives: Everolimus is an immunosuppressant with a small therapeutic window. Its highly variable pharmacokinetics complicates prediction of the individual dose…
Read moreFactors influencing pharmacokinetics of tacrolimus during the early liver post-transplantation period: a population analysis
Thursday 16 October, 2025
Objectives: Tacrolimus (TAC) is an immunosuppressive agent used for the prevention of acute rejection after liver transplantation. Clearance and bioavailability…
Read morePhysiologically based, POP-PK modelling of Strontium Ranelate in the ovariectomised rat disease model of post menopausal osteoporosis.
Thursday 16 October, 2025
Objectives: Strontium is a bone seeking agent currently prescribed for the treatment of post menopausal osteoporosis. The aim of the…
Read moreModelling impact of dropout mechanisms in Chronic Obstructive Pulmonary Disease (COPD)
Thursday 16 October, 2025
Objectives: The objective of this analysis was to investigate the impact of modelling jointly the drug-disease and dropout models to…
Read morePopulation Pharmacokinetics of a Monoclonal Antibody Tanezumab in Chronic Pelvic Pain Conditions
Thursday 16 October, 2025
Objectives: Tanezumab is a fully human monoclonal antibody targeted to the human nerve growth factor receptor (NGF). A comprehensive population…
Read morePK-PD modelling of bone density and turnover effects of denosumab based on a circular model of bone remodelling
Thursday 16 October, 2025
Objectives: To evaluate and update a previously developed bone cycle model (BCM) to describe the long-term effects of denosumab on…
Read more